Al-Hammadi’s net profit jumps 10% to SAR 141 mln in FY15
20/01/2016
Argaam Exclusive
AI Summary
Content Summary: 
Loading data...
Please note that this news summary has been generated using artificial intelligence. It is recommended to review the original
sources for complete details and to verify the accuracy of the information.
View other reports
Al Hammadi Company for Development and Investment, the owner and operator of hospitals in Riyadh, reported a net profit of SAR 141.3 million for the fiscal year 2015, marking a ten percent increase year-on-year (YOY). The company said the profit rise was bolstered by a 16 percent rise in net revenue and collection of SAR 9.8 million written off debt during Q1-2015.
Financials (M)
| Item | 2014 | 2015 | Change |
|---|---|---|---|
| Revenues | 481.96 | 561.33 | 16.5 % |
| Gross Income | 209.11 | 240.24 | 14.9 % |
| Operating Income | 130.95 | 143.57 | 9.6 % |
| Net Income | 128.95 | 141.33 | 9.6 % |
| Average Shares | 160.00 | 160.00 | - |
| Earnings Per Share before unusual items (Riyals) | 0.81 | 0.82 | 2.0 % |
| EPS (Riyal) | 0.81 | 0.88 | 9.6 % |
The fourth-quarter net profit grew by 6 percent YOY to SAR 35.8 million, thanks to higher revenues. Profit for the period was 29 percent compared to the previous quarter.
Compared With The
Current Quarter Comparison (M)
| Item | Q4 2014 | Q4 2015 | Change |
|---|---|---|---|
| Revenues | 129.43 | 157.70 | 21.8 % |
| Gross Income | 55.99 | 68.06 | 21.6 % |
| Operating Income | 34.52 | 40.39 | 17.0 % |
| Net Income | 33.71 | 35.75 | 6.0 % |
| Average Shares | 160.00 | 160.00 | - |
| Earnings Per Share before unusual items (Riyal) | 0.21 | 0.22 | 6.0 % |
| EPS (Riyal) | 0.21 | 0.22 | 6.0 % |
Financial results (Million)
| Period | Revenues | Change | Gross Income | Change | Operating Income | Change |
|---|---|---|---|---|---|---|
| Q1 2015 | 129.48 | 6.1 % | 50.64 | (7.4 %) | 33.35 | (7.3 %) |
| Q2 2015 | 137.36 | 12.9 % | 63.56 | 18.4 % | 37.91 | 6.0 % |
| Q3 2015 | 136.80 | 25.7 % | 57.97 | 29.6 % | 31.92 | 28.8 % |
| Q4 2015 | 157.70 | 21.8 % | 68.06 | 21.6 % | 40.39 | 17.0 % |
| 2015 | 561.33 | 16.5 % | 240.24 | 14.9 % | 143.57 | 9.6 % |
Profit Performance (Million)
| Period | Net Income | Change | EPS(Riyal) | Extraordinary Income/Expense | Net Profit Before Unusual Items | EPS(Riyal) |
|---|---|---|---|---|---|---|
| Q1 2015 | 41.01 | 19.8 % | 0.26 | 9.80 | 31.21 | 0.20 |
| Q2 2015 | 36.89 | 3.6 % | 0.23 | - | 36.89 | 0.23 |
| Q3 2015 | 27.69 | 8.9 % | 0.17 | - | 27.69 | 0.17 |
| Q4 2015 | 35.75 | 6.0 % | 0.22 | - | 35.75 | 0.22 |
| 2015 | 141.33 | 9.6 % | 0.88 | 9.80 | 131.53 | 0.82 |
Profitability
| Period | Gross Margin | OIBDA Margin | Net Margin Before Unusual Items |
|---|---|---|---|
| Q1 2014 | 42.66 % | 27.85 % | 24.35 % |
| Q2 2014 | 43.18 % | 29.90 % | 26.17 % |
| Q3 2014 | 43.70 % | 30.34 % | 26.97 % |
| Q4 2014 | 43.39 % | 30.09 % | 26.75 % |
| 2014 | 43.39 % | 30.07 % | 26.75 % |
| Q1 2015 | 41.90 % | 29.13 % | 25.73 % |
| Q2 2015 | 42.55 % | 28.68 % | 25.19 % |
| Q3 2015 | 42.80 % | 29.71 % | 24.29 % |
| Q4 2015 | 42.80 % | 31.06 % | 23.43 % |
| 2015 | 42.80 % | 31.06 % | 23.43 % |
Compared With The
Per Share Data (Riyal)
| Period | Shares Outstanding (M) | EPS (Riyal) | Earnings Per Share before unusual items (Riyal) | Book Value (BV) |
|---|---|---|---|---|
| Q1 2015 | 160.00 | 0.85 | 0.79 | 8.51 |
| Q2 2015 | 160.00 | 0.86 | 0.80 | 8.27 |
| Q3 2015 | 160.00 | 0.87 | 0.81 | 8.44 |
| Q4 2015 | 160.00 | 0.88 | 0.82 | 8.66 |
Multiple Ratios (End of Period Price)
| Period | P/E | Recurring P/E | Price/book |
|---|---|---|---|
| Q1 2015 | 51.53 | 55.54 | 5.14 |
| Q2 2015 | 54.13 | 58.30 | 5.61 |
| Q3 2015 | 44.33 | 47.69 | 4.57 |
| Q4 2015 | 41.63 | 44.73 | 4.24 |
Business Segments (Million)
2015
| Period | Healthcare services | Pharmaceutical sales revenue - Pharmacies |
|---|
Analysts Estimates (Million)
| Item | Profit (Expected) | Profit (Actual) | Change |
|---|---|---|---|
| Average | 35.47 | 35.75 |
Estimates vs Actual (Million)
| Item | Profit (Expected) | Profit (Actual) | Change |
|---|---|---|---|
| Albilad Capital | 36.00 | 35.75 | |
| OSOOL AND BAKHEET | 36.20 | 35.75 | |
| Value Capital | 37.30 | 35.75 | |
| Alistithmar for Financial Securities and Brokerage | 37.60 | 35.75 | |
| AlJazira Capital | 33.70 | 35.75 | |
| Al Rajhi Capital | 32.00 | 35.75 |
| Current | |
| Market Cap (M Riyal) | 4,860.80 |
| Enterprise Value (EV) (M Riyal) | 5,008.60 |
| Shares Outstanding ((M)) | 160.00 |
| EPS ( Riyal) (TTM) | 1.66 |
| Book Value (BV) ( Riyal) | 12.40 |
| Par Value ( Riyal) | 10.00 |
| Recurring P/E | 18.30 |
| P/E (TTM) | 18.30 |
| Price/book | 2.45 |
| Return on Average Assets (%) (TTM) | 10.0 |
| Return on Average Equity (%) (TTM) | 13.5 |
| EV/adj EBITDA | 14.69 |
| EV/Revenues | 4.11 |
Share Price
Al Hammadi Holding (ALHAMMADI)
Follow us on
Comments {{getCommentCount()}}
Be the first to comment
{{Comments.indexOf(comment)+1}}
رد{{comment.DisplayName}} على {{getCommenterName(comment.ParentThreadID)}}
{{comment.DisplayName}}
{{comment.ElapsedTime}}
Sorry: the validity period has ended to comment on this news
Opinions expressed in the comments section do not reflect the views of Argaam. Abusive comments of any kind will be removed. Political or religious commentary will not be tolerated.
Comments Analysis: